siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells

Kong,Ling‑Ling; Man,Dong‑Mei; Wang,Tian; Zhang,Guo‑An; Cui,Wen

doi:10.3892/ol.2015.3782

siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells

Authors:
- Ling‑Ling Kong
- Dong‑Mei Man
- Tian Wang
- Guo‑An Zhang
- Wen Cui
View Affiliations

Affiliations: Department of Pathology, Basic Science School, Jining Medical University, Jining, Shandong 272067, P.R. China, Department of Gynecology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China, Department of Electrocardiogram, The First Affiliated Hospital of Jining Medical University, Jining, Shandong 272111, P.R. China
Published online on: October 7, 2015 https://doi.org/10.3892/ol.2015.3782
Pages: 3393-3398
Copyright: © Kong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to estimate the effects of small interfering RNA (siRNA) targeting retinoblastoma binding protein 2 (RBP2) on the proliferation, expression, invasion, migration and tumorigenicity abilities of papillary thyroid carcinoma K1 cells, siRNA targeting RBP2 (RBP2-siRNA) and negative control siRNA were transfected into K1 cells. The mRNA levels of RBP2 in the transfected cells were estimated by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), and the protein levels of RBP2 in these cells were evaluated by western blot analysis and immunocytochemical (ICC) analyses. The growth, tumorigenicity, migration and invasion abilities of the transfected cells were measured by Cell Counting Kit‑8 (CCK‑8), soft agar colony formation and transwell chamber assay, respectively. The ICC results demonstrated that the protein expression levels of RBP2 were lower in the RBP2‑siRNA‑transfected cells than in the blank and control cells (analysis of variance, F=26.754, P<0.01). RBP2‑siRNA downregulated RBP2 at the mRNA (t=8.869) and protein level (F=60.835) (P=0.000 vs. control cells). In addition, the transfection of RBP2‑siRNA into K1 cells also suppressed cell proliferation at 24, 48 and 72 h post‑transfection (t=7.650, P<0.01; t=2.606, P=0.016; and t=2.377, P=0.027, respectively). Compared with the control group, the number of invasive and migrated cells were significantly reduced in the RBP2‑siRNA‑transfected group (t=4.774 and t=6.366, respectively; P<0.01). Furthermore, the tumorigenic potential of the cells transfected with RBP2‑siRNA was markedly reduced, as indicated by the soft agar formation assay (t=2.749, P=0.014 vs. control cells). In conclusion, the transfection of RBP2‑siRNA into papillary thyroid carcinoma K1 cells suppressed the expression of RBP2 in these cells, and reduced their proliferation, invasion, migration and tumorigenic potential. Therefore, targeting RBP2 may be an efficient approach to control thyroid carcinoma.

View Figures

View References

1	Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
2	Davies L and Welch HG: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 40:317–322. 2014. View Article : Google Scholar
3	Moura MA, Bergmann A, Aguiar SS and Thuler LC: The magnitude of the association between smoking and the risk of developing cancer in Brazil: A multicenter study. BMJ Open. 4:e0037362014. View Article : Google Scholar : PubMed/NCBI
4	Pilli T, Prasad KV, Jayarama S, Pacini F and Prabhakar BS: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 19:1333–1342. 2009. View Article : Google Scholar : PubMed/NCBI
5	Medici M, Porcu E, Pistis G, Teumer A, Brown SJ, Jensen RA, Rawal R, Roef GL, Plantinga TS, Vermeulen SH, et al: Identification of novel genetic loci associated with thyroid peroxidase antibodies and clinical thyroid disease. PLoS Genet. 10:e10041232014. View Article : Google Scholar : PubMed/NCBI
6	Akeno N, Miller AL, Ma X and Wikenheiser-Brokamp KA: p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene. 34:589–99. 2015. View Article : Google Scholar : PubMed/NCBI
7	Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, et al: Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab. 99:E832–E840. 2014. View Article : Google Scholar : PubMed/NCBI
8	Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
9	Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van Nimwegen E and Christofori G: Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013. View Article : Google Scholar : PubMed/NCBI
10	Enkhbaatar Z, Terashima M, Oktyabri D, Tange S, Ishimura A, Yano S and Suzuki T: KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle. 12:2100–2112. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ramadoss S, Chen X and Wang CY: Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J Biol Chem. 287:44508–44517. 2012. View Article : Google Scholar : PubMed/NCBI
12	Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P, Gilliland DG, Zhang Y and Kaelin WG Jr: The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell. 128:889–900. 2007. View Article : Google Scholar : PubMed/NCBI
13	Christensen J, Agger K, Cloos PA, Pasini D, Rose S, Sennels L, Rappsilber J, Hansen KH, Salcini AE and Helin K: RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 128:1063–1076. 2007. View Article : Google Scholar : PubMed/NCBI
14	Benevolenskaya EV, Murray HL, Branton P, Young RA and Kaelin WG Jr: Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell. 18:623–635. 2005. View Article : Google Scholar : PubMed/NCBI
15	Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
16	Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, et al: Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One. 8:e697842013. View Article : Google Scholar : PubMed/NCBI
17	Wang S, Wang Y, Wu H and Hu L: RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer. PLoS One. 8:e847352013. View Article : Google Scholar : PubMed/NCBI
18	Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX and Yan Q: Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Reports. 6:868–877. 2014. View Article : Google Scholar : PubMed/NCBI
19	Jiping Z, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C and Jihui J: MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. J Cell Biochem. 114:2666–2672. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kong L, Zhang G, Wang X, Zhou J, Hou S and Cui W: Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma. Rom J Morphol Embryol. 54:499–503. 2013.PubMed/NCBI
21	Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 7:21–33. 2006. View Article : Google Scholar : PubMed/NCBI
22	Varier RA and Timmers HT: Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta. 1815:75–89. 2011.PubMed/NCBI
23	Fang Y, Xiao F, An Z and Hao L: Systematic review on the relationship between genetic polymorphisms of methylenetetrahydrofolate reductase and esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 12:1861–1866. 2011.PubMed/NCBI
24	Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, et al: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 448:553–560. 2007. View Article : Google Scholar : PubMed/NCBI
25	Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, Whetstine JR, Bonni A, Roberts TM and Shi Y: The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 128:1077–1088. 2007. View Article : Google Scholar : PubMed/NCBI
26	Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE and Oliff A: Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature. 352:251–254. 1991. View Article : Google Scholar : PubMed/NCBI
27	Teng YC, Lee CF, Li YS, Chen YR, Hsiao PW, Chan MY, Lin FM, Huang HD, Chen YT, Jeng YM, et al: Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res. 73:4711–4721. 2013. View Article : Google Scholar : PubMed/NCBI
28	Blair LP, Cao J, Zou MR, Sayegh J and Yan Q: Epigenetic regulation by lysine demethylase 5 (kdm5) enzymes in cancer. Cancers (Basel). 3:1383–1404. 2011. View Article : Google Scholar : PubMed/NCBI
29	Lin N, Du XL, Reitzel LR, Xu L and Strugis EM: impact of enhanced detection on the increase in thyroid cancer incidence in the United States: Review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid. 23:103–110. 2013. View Article : Google Scholar : PubMed/NCBI